Inozyme Pharma, Inc. INZY
Institutional shares held
46 Million
13.8K
calls
1K
puts
Total value of holdings
$184M
$55K
calls
$4K
puts
Market Cap
$161M
40,145,700
Shares Out.
Institutional ownership
114.66%
# of Institutions
97
We take great care to ensure that the data presented and summarized in this overview for Inozyme Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INZY
View all-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$20.6 Million0.01% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$18 Million5.72% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17.1 Million0.29% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.87MShares$15.5 Million0.39% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.45MShares$13.8 Million0.19% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$13.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.76MShares$11 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD2.44MShares$9.75 Million0.21% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA1.56MShares$6.25 Million0.66% of portfolio
-
Chi Advisors LLC New York, NY1.27MShares$5.08 Million2.63% of portfolio
Latest Institutional Activity in INZY
Top Purchases
Top Sells
About INZY
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Insider Transactions at INZY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2025
|
Sanjay Subramanian SVP, CFO & Head of BD |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
39,701
-100.0%
|
$158,804
$4.0 P/Share
|
|
Jul 01
2025
|
Axel Bolte |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
423,926
-100.0%
|
$1,695,704
$4.0 P/Share
|
|
Jul 01
2025
|
Matthew Winton COO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,743
-100.0%
|
$86,972
$4.0 P/Share
|
|
Jul 01
2025
|
Douglas A Treco CEO & Chairman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
43,861
-100.0%
|
$175,444
$4.0 P/Share
|
|
Jul 01
2025
|
Robert Lorne Hopfner |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,494,851
-100.0%
|
$17,979,404
$4.0 P/Share
|
|
Jun 25
2025
|
Sanjay Subramanian SVP, CFO & Head of BD |
BUY
Grant, award, or other acquisition
|
Direct |
6,813
+14.65%
|
$0
$0.74 P/Share
|
|
Jun 25
2025
|
Douglas A Treco CEO & Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
2,815
+6.03%
|
$0
$0.74 P/Share
|
|
Jun 25
2025
|
Matthew Winton COO |
BUY
Grant, award, or other acquisition
|
Direct |
14,355
+39.77%
|
$0
$0.74 P/Share
|
|
May 15
2025
|
Axel Bolte |
BUY
Exercise of conversion of derivative security
|
Direct |
157,230
+13.87%
|
$0
$0.98 P/Share
|
|
Apr 02
2025
|
Douglas A Treco CEO & Chairman |
SELL
Open market or private sale
|
Direct |
8,819
-17.69%
|
$0
$0.89 P/Share
|
|
Apr 01
2025
|
Douglas A Treco CEO & Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+33.39%
|
-
|
|
Mar 31
2025
|
Sanjay Subramanian SVP, CFO & Head of BD |
BUY
Grant, award, or other acquisition
|
Direct |
2,490
+7.04%
|
$0
$0.77 P/Share
|
|
Mar 31
2025
|
Matthew Winton COO |
BUY
Grant, award, or other acquisition
|
Direct |
2,490
+25.21%
|
$0
$0.77 P/Share
|
|
Sep 30
2024
|
Matthew Winton COO |
BUY
Grant, award, or other acquisition
|
Direct |
1,710
+25.88%
|
$6,840
$4.45 P/Share
|
|
Sep 30
2024
|
Douglas A Treco CEO & Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
1,710
+7.1%
|
$6,840
$4.45 P/Share
|
|
Apr 02
2024
|
Douglas A Treco CEO & Chairman |
SELL
Open market or private sale
|
Direct |
7,523
-26.69%
|
$45,138
$6.94 P/Share
|
|
Apr 01
2024
|
Douglas A Treco CEO & Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+47.0%
|
-
|
|
Mar 28
2024
|
Matthew Winton COO |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+50.0%
|
$9,564
$3.33 P/Share
|
|
Sep 29
2023
|
Sanjay Subramanian SVP, CFO & Head of BD |
BUY
Grant, award, or other acquisition
|
Direct |
2,319
+7.09%
|
$6,957
$3.57 P/Share
|
|
Aug 01
2023
|
Pivotal Bio Venture Partners Fund I, L.P. |
BUY
Open market or private purchase
|
Indirect |
833,333
+17.58%
|
$3,333,332
$4.8 P/Share
|
Last 12 Months Summary
Buy / Acquisition
215K
Shares
From
5
Insiders
| Grant, award, or other acquisition | 32.4K shares |
|---|---|
| Exercise of conversion of derivative security | 182K shares |
Sell / Disposition
5.03M
Shares
From
6
Insiders
| Disposition due to a tender of shares in a change of control transaction | 5.02M shares |
|---|---|
| Open market or private sale | 8.82K shares |